A Phospho-Tau Plasma Assay for Alzheimer’s?
Two papers report that phosphorylated tau in the blood distinguishes people with AD from healthy controls and from people with frontotemporal and vascular dementias.
ALL NEWS
5726 RESULTS
Sort By:
- Most Recent
- Most Commented
Low-Dose Aspirin Does Not Prevent AD, or Slow Cognitive Decline
A trial of nearly 20,000 participants found no benefit over five years.
Which Are the Right Tests to Satisfy New FDA Guidance?
The Food and Drug Administration has said it will accept cognition alone as the basis for approval in preclinical AD. Now what? Industry is confronting the challenge to show robust and meaningful change.
Non-Amyloid Treatments: Inflammation, Epigenetics, Regeneration
A broadening drug development pipeline now contains Phase 1 or 2 drugs on targets unrelated to Aβ or tau.
‘Working from Home’: Do Gut Microbes Hold Sway Over Glia, Aβ?
Scientists report at AAT-AD/PD that they tightened a causal connection between gut microbes, microglial function, and protein deposits. In mice, that is.
Active Tau Vaccine: Hints of Slowing Neurodegeneration
In a Phase 2 trial, the vaccine reportedly normalized the rise in plasma NfL, and appeared to lower CSF tau and retard brain atrophy.
Tau Receptor Identified on Cell Surface
At Tau2020 conference, scientists implicate LDL receptor-related protein 1 in cell-to-cell transmission.
New Alzheimer’s and Parkinson’s Immunotherapy Data at AAN
Biogen showed results from clinical trials of anti-Aβ and anti-α-synuclein antibodies at the American Academy of Neurology annual meeting.
With TREM2, Timing Is Everything
In a mouse model of amyloidosis, human wild-type TREM2 kept Aβ deposition at bay early on, but this defense became overwhelmed as plaques grew. The R47H AD risk variant never offered protection early on, and made things worse later.
α-Synuclein Antibody Misses Primary, May Have Signal on Secondaries
The first topline Phase 2 results from an antibody targeting Parkinson’s pathology, Roche’s prasinezumab, were a mixed bag. Next steps are unclear.
AAT-AD/PD™ 2020 Conference: Advances in Alzheimer's and Parkinson's Therapies
New Assay, New Cohorts—Plasma p-Tau181 Looks Even Better 217—The Best Phospho-Tau Marker for Alzheimer’s? In DIAN-TU, Gantenerumab Brings Down Tau. By a Lot. Open Extension Planned Confused About the DIAN-TU Trial Data? Experts Discuss Active Tau Vaccine: ...
Non-Aβ, Non-Tau Drugs Tweak Markers, Cognition in Alzheimer’s, Huntington’s
Researchers at the online AAT-AD/PD meeting touted therapies that target neuroinflammation, synapses, epigenetic regulation, or the cortisol stress response.
Antisense Oligonucleotides: Can They Take on ALS, SMA, Prions?
Data on ASOs, presented recently at the annual meeting of the American Academy of Neurology, depict RNA-based therapies as broadly on the rise in neurodegenerative diseases.
Adding ALS to the Manifestations of VCP Mutations
In hunting for mutations that cause ALS, researchers discovered that VCP mutations, long thought to spare the spine, are instead a cause of inherited ALS...
Which Cell Types Execute Your Genetic Risk? For AD and PD, Scientists Know.
For several neurodegenerative diseases, scientists identified which cell types exert a person’s inherited risk. In Alzheimer’s, it’s microglia; in Parkinson’s, it’s dopaminergic and enteric neurons—and oligodendrocytes.
Current Filters
- Date Range : All x